Review of the contribution of radiolabelled tracers for tumour cell status imaging

Current Medical Imaging Reviews

Volumn 2, Issue 2, 2006, Pages 193-203

  Nathalie, Perek ^a   Nathalie, Le Jeune ^a   Delphine, Denoyer ^a   Nathalie, Prevot ^a   Dubois, Francis ^a  

^a UNIVERSITÉ JEAN MONNET   (France)

Author keywords

Apoptosis; MDR; PET; Proliferation; Radiotracer; SPECT; Tumour metabolism

Indexed keywords

3' FLUOROTHYMIDINE; ANTINEOPLASTIC AGENT; BROXURIDINE; CARBON 11; CARBOXYL GROUP; CHOLINE DERIVATIVE; CLEVUDINE; DNA; DOPA; FLUORINE 18; FLUORINE DERIVATIVE; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; HEMICHOLINIUM 3; IDOXURIDINE; IODINE 124; LEUCINE; LIPID; LIPOCORTIN 5; METHIONINE; METIROSINE; MULTIDRUG RESISTANCE PROTEIN 1; PHENYLALANINE DERIVATIVE; PHOSPHATE; SUCCIMER TC 99M; TECHNETIUM 99M; TRACER; TYROSINE; TYROSINE DERIVATIVE; UNINDEXED DRUG;

AMINO ACID METABOLISM; AMINO ACID TRANSPORT; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER MODEL; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DNA SYNTHESIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG SELECTIVITY; GLYCOLYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIPID METABOLISM; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; METASTASIS; MOLECULAR BIOLOGY; MOLECULAR IMAGING; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEAR MEDICINE; ONCOLOGY; PHOSPHATE METABOLISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR CELL;

EID: 33745809503     PISSN: 15734056     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340506776930647     Document Type: Review

References (116)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-98.
3. Kapoor V, McCook BM, Torok FS. An introduction to PET-CT imaging. Radiographics 2004; 24: 523-43.
4. Cohade C, Wahl RL. PET scanning and measuring the impact of treatment. Cancer J 2002; 8: 119-34.
5. Couturier O, Luxen A, Chatal JF, Vuillez JP, Rigo P, Hustinx R. Fluorinated tracers for imaging cancer with positron emission tomography. Eur J Nucl Med Mol Imaging 2004; 31: 1182-206. Epub 2004 Jul 06.
6. Kotzki PO. [Positron emission tomography: a clinical and biological research tool]. J Soc Biol 2004; 198: 163-8.
7. Higashi K, Matsunari I, Ueda Y, et al. Value of whole-body FDG PET in management of lung cancer. Ann Nucl Med 2003; 17: 1-14.
8. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231: 305-32. Epub 2004 Mar 24.
9. Dittmann H, Dohmen BM, Paulsen F, et al. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 2003; 30: 1407-12. Epub 2003 Jul 26.
10. Otsuka H, Graham M, Kubo A, Nishitani H. Clinical utility of FDG PET. J Med Invest 2004; 51: 14-9.
11. Hwang K, Park CH, Kim HC, et al. Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography. Clin Nucl Med 2000; 25: 789-95.
12. Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer lymphoma and melanoma. J Nucl Med 1999; 40: 591-603.
13. Kumar R, Mavi A, Bural G, Alavi A. Fluorodeoxyglucose-PET in the management of malignant melanoma. Radiol Clin North Am 2005; 43: 23-33.
14. Bellon JR, Livingston RB, Eubank WB, et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 2004; 27: 407-10.
15. Smyczek-Gargya B, Fersis N, Dittmann H, et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004; 31: 720-4. Epub 2004 Feb 19.
16. Been LB, Suurmeijer AJ, Cobben DC, Jager PL, Hoekstra HJ, Elsinga PH. [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 2004; 31: 1659-72.
17. Paik JY, Lee KH, Choe YS, Choi Y, Kim BT. Augmented 18F-FDG uptake in activated monocytes occurs during the priming process and involves tyrosine kinases and protein kinase C. J Nucl Med 2004; 45: 124-8.
18. Stroobants S, Goeminne J, Seegers M, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39: 2012-20.
19. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996; 23: 1409-15.
20. Cook GJ, Wegner EA, Fogelman I. Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med 2004; 34: 122-33.
21. El-Haddad G, Zhuang H, Gupta N, Alavi A. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 2004; 34: 313-29.
22. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999; 19: 61-77; quiz 150-1.
23. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996; 26: 308-14.
24. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004; 34: 274-92.
25. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002; 168: 273-80.
26. Papantoniou V, Christodoulidou J, Papadaki E, et al. 99mTc-(V)DMSA scintimammography in the assessment of breast lesions: comparative study with 99mTc-MIBI. Eur J Nucl Med 2001; 28: 923-8.
27. Hirano T, Otake H, Kazama K, et al. Technetium-99m(V)-DMSA and thallium-201 in brain tumor imaging: correlation with histology and malignant grade. J Nucl Med 1997; 38: 1741-9.
28. Hirano T, Otake H, Shibasaki T, Tamura M, Endo K. Differentiating histologic malignancy of primary brain tumors: pentavalent technetium-99m-DMSA. J Nucl Med 1997; 38: 20-6.
29. Hirano T, Otake H. Bone metastases demonstrated by pentavalent Tc-99m DMSA and Tc-99m HMDP. Clin Nucl Med 1997; 22: 640-1.
30. Lam AS, Kettle AG, O'Doherty MJ, Coakley AJ, Barrington SF, Blower PJ. Pentavalent 99Tcm-DMSA imaging in patients with bone metastases. Nucl Med Commun 1997; 18: 907-14.
31. Atasever T, Gundogdu C, Vural G, Kapucu LO, Karalezli A, Unlu M. Evaluation of pentavalent Tc-99m DMSA scintigraphy in small cell and nonsmall cell lung cancers. Nuklearmedizin 1997; 36: 223-7.
32. Blower PJ, Singh J, Clarke SE. The chemical identity of pentavalent technetium-99m-dimercaptosuccinic acid [see comments]. J Nucl Med 1991; 32: 845-9.
33. Lam ASK, Puncher MR, Blower PJ. In vitro and in vivo studies with pentavalent technetium-99m dimercaptosuccinic acid. Eur J Nucl Med 1996; 23: 1575-82.
34. Horiuchi K, Saji H, Yokoyama A. pH sensitive properties of Tc(V)-DMS: analytical and in vitro cellular studies. Nucl Med Biol 1998; 25: 689-95.
35. Horiuchi K, Saji H, Yokoyama A. Tc(V)-DMS tumor localization mechanism: a pH-sensitive Tc(V)-DMS- enhanced target/nontarget ratio by glucose-mediated acidosis. Nucl Med Biol 1998; 25: 549-55.
36. Yokoyama A, Hata N, Horiuchi K, et al. The design of a pentavalent 99mTc-dimercaptosuccinate complex as a tumor imaging agent. Int J Nucl Med Biol 1985; 12: 273-9.
37. Werner A, Kinne RK. Evolution of the Na-P(i) cotransport systems. Am J Physiol Regul Integr Comp Physiol 2001; 280: R301-12.
38. Denoyer D, Perek N, Le Jeune N, Frere D, Dubois F. Evidence that 99mTc-(V)-DMSA uptake is mediated by NaPi cotransporter type III in tumour cell lines. Eur J Nucl Med Mol Imaging 2004; 31: 77-84. Epub 2003 Oct 14.
39. Hernando N, Gisler SM, Pribanic S, et al. NaPi-IIa and interacting partners. J Physiol 2005; 567: 21-6. Epub 2005 May 12.
40. Denoyer D, Perek N, Jeune NL, et al. In vitro and in vivo evaluation of the influence of type III NaPi co-transporter activity during apoptosis on 99mTc-(V)DMSA uptake in the human leukaemic cell line U937. Eur J Nucl Med Mol Imaging 2004; 31: 1421-7. Epub 2004 Jun 16.
41. Gibbs JB. Anticancer drug targets: growth factors and growth factor signaling. J Clin Invest 2000; 105: 9-13.
42. Denoyer D, Perek N, Le Jeune N, Cornillon J, Dubois F. Correlation between(99m)Tc-(V)-DMSA uptake and constitutive level of phosphorylated focal adhesion kinase in an in vitro model of cancer cell lines. Eur J Nucl Med Mol Imaging 2005; 23: 23.
43. Ishiwata K, Kubota K, Murakami M, et al. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med 1993; 34: 1936-43.
44. Vaalburg W, Coenen HH, Crouzel C, et al. Amino acids for the measurement of protein synthesis in vivo by PET. Int J Rad Appl Instrum B 1992; 19: 227-37.
45. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993; 34: 773-9.
46. Kubota K, Yamada S, Ishiwata K, et al. Evaluation of the treatment response of lung cancer with positron emission tomography and L-[methyl-11C] methionine: a preliminary study. Eur J Nucl Med 1993; 20: 495-501.
47. Weber WA, Wester HJ, Grosu AL, et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000; 27: 542-9.
48. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of solitary pulmonary nodules with positron emission tomography using [11C]L-methionine. J Comput Assist Tomogr 1988; 12: 794-6.
49. Hatazawa J, Ishiwata K, Itoh M, et al. Quantitative evaluation of L-[methyl-C-11] methionine uptake in tumor using positron emission tomography. J Nucl Med 1989; 30: 1809-13.
50. Minn H, Clavo AC, Grenman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med 1995; 36: 252-8.
51. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991; 32: 623-48; discussion 649-50.
52. Kole AC, Plaat BE, Hoekstra HJ, Vaalburg W, Molenaar WM. FDG and L-[1-11C]-tyrosine imaging of soft-tissue tumors before and after therapy. J Nucl Med 1999; 40: 381-6.
53. Ishiwata K, Kawamura K, Wang WF, et al. Evaluation of O-[11C]methyl-L-tyrosine and O-[18F]fluoromethyl-L-tyrosine as tumor imaging tracers by PET. Nucl Med Biol 2004; 31: 191-8.
54. Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 1999; 40: 205-12.
55. Heiss P, Mayer S, Herz M, Wester HJ, Schwaiger M, Senekowitsch-Schmidtke R. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med 1999; 40: 1367-73.
56. Tomiyoshi K, Amed K, Muhammad S, et al. Synthesis of isomers of 18F-labelled amino acid radiopharmaceutical: position 2- and 3-L-18F-alpha-methyltyrosine using a separation and purification system. Nucl Med Commun 1997; 18: 169-75.
57. Watanabe H, Inoue T, Shinozaki T, et al. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med 2000; 27: 1509-17.
58. Inoue T, Koyama K, Oriuchi N, et al. Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG - preliminary study. Radiology 2001; 220: 54-62.
59. Inoue T, Tomiyoshi K, Higuichi T, et al. Biodistribution studies on L-3-[fluorine-18]fluoro-alpha-methyl tyrosine: a potential tumor-detecting agent. J Nucl Med 1998; 39: 663-7.
60. Rau FC, Weber WA, Wester HJ, et al. O-(2-[(18)F]Fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging 2002; 29: 1039-46. Epub 2002 May 28.
61. Kaim AH, Weber B, Kurrer MO, et al. (18)F-FDG and (18)F-FET uptake in experimental soft tissue infection. Eur J Nucl Med Mol Imaging 2002; 29: 648-54. Epub 2002 Mar 06.
62. Kubota R, Yamada S, Ishiwata K, Kubota K, Ido T. Active melanogenesis in non-S phase melanocytes in B16 melanomas in vivo investigated by double-tracer microautoradiography with 18F-fluorodopa and 3H-thymidine. Br J Cancer 1992; 66: 614-8.
63. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001; 28: 64-71.
64. Hoegerle S, Ghanem N, Altehoefer C, et al. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 2003; 30: 689-94. Epub 2003 Mar 5.
65. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 2003; 90: 525-33.
66. Aoyama C, Liao H, Ishidate K. Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res 2004; 43: 266-81.
67. Hara T. 18F-fluorocholine: a new oncologic PET tracer. J Nucl Med 2001; 42: 1815-7.
68. Hara T, Inagaki K, Kosaka N, Morita T. Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. J Nucl Med 2000; 41: 1507-13.
69. Narayanan TK, Said S, Mukhedee J, et al. A comparative study on the uptake and incorporation of radiolabeled methionine, choline and fluorodeoxyglucose in human astrocytoma. Mol Imaging Biol 2002; 4: 147-56.
70. Ohtani T, Kurihara H, Ishiuchi S, et al. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med 2001; 28: 1664-70.
71. Khan N, Oriuchi N, Zhang H, et al. A comparative study of 11C-choline PET and [18F]fluorodeoxyglucose PET in the evaluation of lung cancer. Nucl Med Commun 2003; 24: 359-66.
72. Zhang H, Tian M, Oriuchi N, et al. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET. Nucl Med Commun 2003; 24: 273-9.
73. Khan N, Oriuchi N, Ninomiya H, Higuchi T, Kamada H, Endo K. Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET. Ann Nucl Med 2004; 18: 409-17.
74. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 2002; 42: 18-23.
75. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 39: 990-5.
76. DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001; 42: 1805-14.
77. Hara T. 11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol 2002; 4: 267-73.
78. Henriksen G, Herz M, Hauser A, Schwaiger M, Wester HJ. Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[18F]fluorocholine ([18F]dOC). Nucl Med Biol 2004; 31: 851-8.
79. Wyss MT, Weber B, Honer M, et al. 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur J Nucl Med Mol Imaging 2004; 31: 312-6. Epub 2003 Nov 20.
80. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am 2005; 43: 153-67.
81. van Eijkeren ME, De Schryver A, Goethals P, et al. Measurement of short-term 11C-thymidine activity in human head and neck tumours using positron emission tomography (PET). Acta Oncol 1992; 31: 539-43.
82. Mariani G, Di Sacco S, Volterrani D, et al. Tumor targeting by intra-arterial infusion of 5-[123I]iodo-2′-deoxyuridine in patients with liver metastases from colorectal cancer. J Nucl Med 1996; 37: 22S-25S.
83. Boni R, Blauenstein P, Dummer R, von Schulthess GK, Schubiger PA, Steinert HC. Non-invasive assessment of tumour cell proliferation with positron emission tomography and [76Br]bromodeoxyuridine. Melanoma Res 1999; 9: 569-73.
84. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 2003; 44: 2027-32.
85. Grierson, JR, Schwartz JL, Muzi M, Jordan R, Krohn KA. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: Validations for positron emission tomography. Nucl Med Biol 2004; 31: 829-37.
86. Barthel H, Cleij MC, Collingridge DR, et al. 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003; 63: 3791-8.
87. Barthel H, Perumal M, Latigo J, et al. The uptake of 3′-deoxy-3′-[(18)F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 2004; 4: 4.
88. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4: 1334-6.
89. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3′-deoxy-3′fluorothymidine uptake. Nucl Med Biol 2004; 31: 419-23.
90. van Waarde A, Cobben DC, Summeijer AJ, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004; 45: 695-700.
91. Dittmann, H, Dohmen BM, Kehlbach R, et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002; 29: 1462-9. Epub 2002 Sep 06.
92. Francis DL, Visvikis D, Costa DC, et al. Potential impact of [18F]3′-deoxy-3′-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003; 30: 988-94. Epub 2003 May 09.
93. Buck AK, Hetzel M, Schirrmeister H, et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 2004; 14: 14.
94. Visvikis D, Francis D, Mulligan R, et al. Comparison of methodologies for the in vivo assessment of (18)FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging 2003; 14: 14.
95. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002; 8: 3315-23.
96. Reed JC. Dysregulation of Apoptosis in Cancer. J Clin Oncol 1999; 17: 2941.
97. Blankenberg F, Ohtsuki K, Strauss HW. Dying a thousand deaths. Radionuclide imaging of apoptosis. Q J Nucl Med 1999; 43: 170-6.
98. Blankenberg FG, Tait J, Ohtsuki K, Strauss HW. Apoptosis: the importance of nuclear medicine. Nucl Med Commun 2000; 21: 241-50.
99. Blankenberg FG, Naumovski L, Tait JF, Post AM, Strauss HW. Imaging cyclophosphamide-induced intramedullary apoptosis in rats using 99mTc-radiolabeled annexin V. J Nucl Med 2001; 42: 309-16.
100. Mochizuki T, Kuge Y, Zhao S, et al. Detection of apoptotic tumor response in vivo after a single dose of chemotherapy with 99mTc-annexin V. J Nucl Med 2003; 44: 92-7.
101. Collingridge DR, Glaser M, Osman S, et al. In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope. Br J Cancer 2003; 89: 1327-33.
102. Blankenberg FG. Recent advances in the imaging of programmed cell death. Curr Pharm Des 2004; 10: 1457-67.
103. Perek N, Denoyer D. The multidrug resistance mechanisms and their interactions with the radiopharmaceutical probes used for an in vivo detection. Curr Drug Metab 2002; 3: 97-113.
104. Piwnica-Worms D, Chiu ML, Kronauge JF. Detection of adriamycin-induced cardiotoxicity in cultured heart cells with technetium 99m-SESTAMIBI. Cancer Chemother Pharmacol 1993; 32: 385-91.
105. Barbarics E, Kronauge JF, Cohen D, Davison A, Jones AG, Croop JM. Characterization of P-glycoprotein transport and inhibition in vivo. Cancer Res 1998; 58: 276-82.
106. Hendrikse NH, Franssen EJ, van der Graaf WT, et al. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer 1998; 77: 353-8.
107. Dirlik A, Burak Z, Goksel T, et al. The role of Tc-99m sestamibi imaging in predicting clinical response to chemotherapy in lung cancer. Ann Nucl Med 2002; 16: 103-8.
108. Zhang Y,, Mack P, Wong KP. Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int J Oncol 1998; 12: 871-82.
109. Perek N, Prevot N, Koumanov F, Frere D, Sabido O, Beauchesne P, Dubois F. Involvement of the glutathione S-conjugate compounds and the MRP protein in Tc-99m-tetrofosmm and Tc-99m-sestamibi uptake in glioma cell lines. Nucl Med Biol 2000; 27: 299-307.
110. Perek N, Koumanov F, Denoyer D, Boudard D, Dubois F. Modulation of the multidrug resistance of glioma by glutathione levels depletion - interaction with Tc-99M-Sestamibi and Tc-99-M-Tetrofosmin. Cancer Biother Radiopharm 2002; 17: 291-302.
111. Le Jeune N, Perek N, Denoyer D, Dubois F. Study of monoglutathionyl conjugates Tc-99m-Sestamibi (MIBI) and Tc-99m-Tetrofosmin (TFOS) transport mediated by the multidrug resistance-associated protein isoform 1 (MRP-1) in glioma cells. under press 2005.
112. Le Jeine N, Perek N, Denoyer D, Dubois F. Influence of glutathione depletion on plasma membrane cholesterol esterification and on Tc-99m-sestamibi and Tc-99m-tetrofosmin uptakes: a comparative study in sensitive U-87-MG and multidrug-resistant MRP1 human glioma cells. Cancer Biother Radiopharm 2004; 19: 411-21.
113. Liu TJ, Shiau YC, Tsai SC, Wang JJ, Ho ST, Kao A. Predicting multidnig resistance-related protein and P-glycoprotein expression with technetium-99m tetrofosmin mammoscintigraphy. Breast 2003; 12: 58-62.
114. Kuo TH, Liu FY, Chuang CY, Wu HS, Wang JJ, Kao A. To predict response chemotherapy using technetium-99m tetrofosmin chest images in patients with untreated small cell lung cancer and compare with p-glycoprotein, multidrug resistance related protein-1, and lung resistance-related protein expression. Nucl Med Biol 2003; 30: 627-32.
115. Shiau YC, Tsai SC, Wang JJ, Ho YJ, Ho ST, Kao CH. To predict chemotherapy response using technetium-99m tetrofosmin and compare with p-glycoprotein and multidrug resistance related protein-1 expression in patients with untreated small cell lung cancer. Cancer Lett 2001; 169: 181-8.
116. Fuster D, Vinolas N, Mallafre C, Pavia J, Martin F, Pons F. Tetrofosmin as predictors of tumour response. Q J Nucl Med 2003; 47: 58-62.